Access the full text.
Sign up today, get DeepDyve free for 14 days.
N. Galiè, A. Hinderliter, A. Torbicki, T. Fourme, G. Simonneau, T. Pulido, N. Espinola-Zavaleta, G. Rocchi, A. Manes, R. Frantz, M. Kurzyna, S. Nagueh, R. Barst, R. Channick, K. Dujardin, Andrew Kronenberg, I. Leconte, M. Rainisio, L. Rubin (2003)
Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension.Journal of the American College of Cardiology, 41 8
N. Galie, A. Torbicki, R. Barst (2004)
Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of CardiologyEur Heart J, 25
J. Dingemanse, P. Giersbergen (2004)
Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor AntagonistClinical Pharmacokinetics, 43
S. Provencher, O. Sitbon, G. Simonneau (2005)
Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidenceExpert Opin Pharmacother, 6
V. McLaughlin, K. Presberg, R. Doyle, S. Abman, D. Mccrory, T. Fortin, G. Ahearn (2004)
Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.Chest, 126 1 Suppl
A. Widlitz, R.J. Barst (2003)
Pulmonary arterial hypertension in childrenEur Respir J, 21
G. Paul, J. Gibbs, A. Boobis, A. Abbas, M. Wilkins (2005)
Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension.British journal of clinical pharmacology, 60 1
E.B. Rosenzweig, D.D. Ivy, A. Widlitz (2005)
Effects of long-term bosentan in children with pulmonary arterial hypertensionJ Am Coll Cardiol, 46
O. Sitbon, V. Gressin, R. Speich, P. Macdonald, M. Opravil, D. Cooper, T. Fourme, M. Humbert, J. Delfraissy, G. Simonneau (2004)
Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension.American journal of respiratory and critical care medicine, 170 11
Eleanor Segal, Cécile Valette, L. Oster, Luc Bouley, Catarina Edfjall, Peter Herrmann, Massimo Raineri, Mary Kempff, Saundra Beacham, Cinda Lierop (2005)
Risk Management Strategies in the Postmarketing PeriodDrug Safety, 28
S. Rich, D.R. Dantzker, S.M. Ayres (1987)
Primary pulmonary hypertension: a national prospective studyAnn Intern Med, 107
I. Binet, A. Wallnöfer, C. Weber (2000)
Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine AKidney Int, 57
C. Weber, R. Schmitt, H. Birnboeck (1996)
Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjectsClin Pharmacol Ther, 60
M.R. Wilkins, G.A. Paul, J.W. Strange (2005)
Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) studyAm J Respir Crit Care Med, 171
M.M. Hoeper, C. Faulenbach, H. Golpon (2004)
Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertensionEur Respir J, 24
V.V. McLaughlin, O. Sitbon, D.B. Badesch (2005)
Survival with first-line bosentan in patients with primary pulmonary hypertensionEur Respir J, 25
S. Provencher, O. Sitbon, M. Humbert (2006)
Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertensionEur Heart J, 27
C. Weber, L. Banken, H. Birnboeck (1999)
Effect of endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarinJ Clin Pharmacol, 39
P.L.M. Giersbergen, A. Halabi, J. Dingemanse (2006)
Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiolInt J Clin Pharmacol Ther, 44
C. Weber, L. Banken, H. Birnboeck (1999)
The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjectsBr J Clin Pharmacol, 47
O. Sitbon, M. Humbert, X. Jaïs, V. Ioos, A. Hamid, S. Provencher, Gilles Garcia, F. Parent, P. Hervé, G. Simonneau (2005)
Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial HypertensionCirculation, 111
P.L. Giersbergen, G. Popescu, F. Bodin (2003)
Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonistJ Clin Pharmacol, 43
M.M. Hoeper, I. Markevych, E. Spiekerkoetter (2005)
Goal-oriented treatment and combination therapy for pulmonary arterial hypertensionEur Respir J, 26
M. Clozel, V. Breu, G.A. Gray (1994)
Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonistJ Pharmacol Exp Ther, 270
O. Sitbon, V. McLaughlin, D. Badesch, R. Barst, C. Black, N. Galiè, M. Humbert, M. Rainisio, Lewis Rubin, G. Simonneau (2005)
Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenolThorax, 60
E.S. Segal, C. Valette, L. Oster (2005)
Risk management strategies in the postmarketing period: safety experience with the US and European bosentan surveillance programmesDrug Saf, 11
C. Weber, R. Schmitt, H. Birnboeck, G. Hopfgartner, H. Eggers, Joseph Meyer, S. Marle, Henk Viischer, J. Jonkman (1999)
Multiple‐Dose Pharmacokinetics, Safety, and Tolerability of Bosentan, an Endothelin Receptor Antagonist, in Healthy Male VolunteersThe Journal of Clinical Pharmacology, 39
M.M. Hoeper (2005)
Drug treatment of pulmonary arterial hypertension: current and future agentsDrugs, 10
D.B. Taichman, J. Shin, L. Hud (2005)
Health-related quality of life in patients with pulmonary arterial hypertensionRespir Res, 6
G. Simonneau, N. Galiè, Lewis Rubin, D. Langleben, W. Seeger, G. Domenighetti, S. Gibbs, D. Lebrec, R. Speich, M. Beghetti, S. Rich, A. Fishman (2004)
Clinical classification of pulmonary hypertension.Journal of the American College of Cardiology, 43 12 Suppl S
N. Galie, A. Manes, A. Branzi (2004)
The endothelin system in pulmonary arterial hypertensionCardiovasc Res, 61
J. Korn, M. Mayes, M. Cerinic, M. Rainisio, J. Pope, E. Hachulla, É. Rich, P. Carpentier, J. Molitor, J. Seibold, V. Hsu, L. Guillevin, Sharmila Chatterjee, H. Peter, J. Coppock, A. Herrick, P. Merkel, R. Simms, C. Denton, D. Furst, N. Nguyen, M. Gaitonde, C. Black (2004)
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.Arthritis and rheumatism, 50 12
J.R. Wu-Wong, D.B. Dixon, W.J. Chiou (1997)
Endothelin receptor antagonists: effect of serum albumin on potency and comparison of pharmacological characteristicsJ Pharmacol Exp Ther, 281
P. Giersbergen, A. Halabi, J. Dingemanse (2002)
Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole.British journal of clinical pharmacology, 53 6
M. Humbert, R.J. Barst, I.M. Robbins (2004)
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2Eur Respir J, 24
R.J. Barst, D. Ivy, J. Dingemanse (2003)
Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertensionClin Pharmacol Ther, 73
H. Yuyama, Y. Noguchi, A. Fujimori (2004)
Superiority of YM598 over atrasentan as a selective endothelin ETA receptor antagonistEur J Pharmacol, 498
L.J. Rubin, D.B. Badesch, R.J. Barst (2002)
Bosentan therapy for pulmonary arterial hypertensionN Engl J Med, 346
D. Badesch, F. Bodin, R. Channick, A. Frost, M. Rainisio, I. Robbins, S. Roux, L. Rubin, G. Simonneau, O. Sitbon, V. Tapson (2002)
Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertensionCurrent Therapeutic Research-clinical and Experimental, 63
A. Ramirez, J. Varga (2004)
Pulmonary Arterial Hypertension in Systemic SclerosisTreatments in Respiratory Medicine, 3
P. Giersbergen, A. Treiber, M. Clozel, F. Bodin, J. Dingemanse (2002)
In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburideClinical Pharmacology & Therapeutics, 71
D. Badesch, S. Abman, G. Ahearn, R. Barst, D. Mccrory, G. Simonneau, V. McLaughlin (2004)
Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice GuidelinesChest, 126
J. Dingemanse, F. Bodin, E. Weidekamm (2002)
Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonistJ Clin Pharmacol, 42
I. Schulze-Neick, N. Gilbert, R. Ewert, C. Witt, E. Gruenig, B. Enke, M. Borst, P. Lange, M. Hoeper (2005)
Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy.American heart journal, 150 4
O. Sitbon, D.B. Badesch, R.N. Channick (2003)
Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up studyChest, 124
S. Sasayama, T. Kunieda, H. Tomoike (2005)
Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertensionCirc J, 69
Z.W. Ghamra, R.A. Dweik (2003)
Primary pulmonary hypertension: an overview of epidemiology and pathogenesisCleve Clin J Med, 70
Y. Braun-Moscovici, A.M. Nahir, A. Balbir-Gurman (2004)
Endothelin and pulmonary arterial hypertensionSemin Arthritis Rheum, 34
J. Dingemanse, Dieter Schaarschmidt, P. Giersbergen (2003)
Investigation of the Mutual Pharmacokinetic Interactions Between Bosentan, a Dual Endothelin Receptor Antagonist, and SimvastatinClinical Pharmacokinetics, 42
J. Dingemanse, P.L.M. Giersbergen (2002)
Influence of severe renal dysfunction on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonistInt J Clin Pharmacol Ther, 40
N. Galiè, M. Beghetti, M. Gatzoulis, J. Granton, R. Berger, Andrea Lauer, E. Chiossi, M. Landzberg (2005)
BREATHE-5: BOSENTAN IMPROVES HEMODYNAMICS AND EXERCISE CAPACITY IN THE FIRST RANDOMIZED PLACEBO-CONTROLLED TRIAL IN EISENMENGER PHYSIOLOGYChest, 128
Z. Yang, N. Krasnići, T. Lüscher (1999)
Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade.Circulation, 100 1
A. Ramirez, J. Varga (2004)
Pulmonary arterial hypertension in systemic sclerosis: clinical manifestations, pathophysiology, evaluation, and managementTreat Respir Med, 6
C. Weber, R. Gasser, G. Hopfgartner (1999)
Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjectsDrug Metab Dispos, 27
M. Humbert, N. Morrell, S. Archer, K. Stenmark, M. MacLean, I. Lang, B. Christman, E. Weir, O. Eickelberg, N. Voelkel, M. Rabinovitch (2004)
Cellular and molecular pathobiology of pulmonary arterial hypertension.Journal of the American College of Cardiology, 43 12 Suppl S
N. Kunichika, J.W. Landsberg, Y. Yu (2004)
Bosentan inhibits transient receptor potential channel expression in pulmonary vascular myocytesAm J Respir Crit Care Med, 170
the treatment of pulmonary arterial hypertension (PAH). The efficacy of oral bosentan 125mg twice daily in improving exercise capacity has been demonstrated in well designed trials in adult patients with idiopathic PAH or PAH associated with connective tissue disease or congenital systemic-to-pulmonary shunts, and in other trials in patients with idiopathic PAH or PAH associated with congenital heart disease or HIV infection. The beneficial effects of first-line bosentan treatment may be maintained for up to 1 year in patients with idiopathic PAH or PAH associated with connective tissue disease. Despite the potential for treatment-related teratogenicity and hepatotoxicity, long-term data indicate that bosentan is generally well tolerated at the approved dosages. Although well designed trials are required to establish the efficacy of bosentan versus or in combination with other specific PAH therapies, especially sildenafil, the convenient oral administration and lack of serious injection-related adverse effects may render bosentan preferable to other PAH therapies. Preliminary data indicate that bosentan may be effective in pediatric PAH patients, although randomized trials are required. Furthermore, bosentan may be a useful option for the prevention of digital ulcer development in patients with systemic sclerosis. Thus, in accordance with current clinical guidelines, bosentan is a convenient,
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 20, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.